NASDAQ:BCRX - BioCryst Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $16.00
  • Forecasted Upside: -0.62 %
  • Number of Analysts: 9
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 7 Buy Ratings
  • 0 Strong Buy Ratings
▼ -0.02 (-0.12%)

This chart shows the closing price for BCRX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New BioCryst Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BCRX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BCRX

Analyst Price Target is $16.00
▼ -0.62% Downside Potential
This price target is based on 9 analysts offering 12 month price targets for BioCryst Pharmaceuticals in the last 3 months. The average price target is $16.00, with a high forecast of $21.00 and a low forecast of $6.00. The average price target represents a -0.62% upside from the last price of $16.10.

This chart shows the closing price for BCRX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 9 polled investment analysts is to buy stock in BioCryst Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 8 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/17/2021CowenBoost Price TargetOutperform$18.00 ➝ $21.00Low
5/28/2021Piper SandlerBoost Price TargetOverweight$15.00 ➝ $18.00High
5/7/2021Evercore ISIBoost Price Target$16.00 ➝ $20.00Medium
5/7/2021BarclaysBoost Price TargetOverweight$13.00 ➝ $20.00High
4/15/2021Needham & Company LLCReiterated RatingHoldHigh
3/24/2021HC WainwrightBoost Price TargetBuy$14.00 ➝ $19.00High
3/17/2021JPMorgan Chase & Co.Boost Price TargetPositive ➝ Overweight$10.00 ➝ $15.00Medium
3/1/2021CowenInitiated CoverageOutperform$16.00Low
2/26/2021BarclaysBoost Price TargetOverweight$9.00 ➝ $13.00Low
1/22/2021Royal Bank of CanadaBoost Price TargetSector Perform$7.00 ➝ $9.00High
12/7/2020HC WainwrightBoost Price TargetBuy$13.00 ➝ $14.00High
11/23/2020Evercore ISIInitiated CoverageOutperform$12.00High
10/4/2020Bank of AmericaReiterated RatingBuy$6.00High
9/29/2020JPMorgan Chase & Co.Initiated CoverageOverweightMedium
8/28/2020Royal Bank of CanadaReiterated RatingHold$4.50High
8/7/2020HC WainwrightReiterated RatingBuy$13.00Low
7/6/2020Royal Bank of CanadaReiterated RatingHold$5.00Low
6/26/2020JMP SecuritiesBoost Price TargetOutperform$10.00 ➝ $11.00High
6/16/2020BTIG ResearchInitiated CoverageNeutralHigh
6/8/2020Piper SandlerReiterated RatingBuy$10.00Medium
5/7/2020Royal Bank of CanadaReiterated RatingHold$4.00Low
5/6/2020Needham & Company LLCReiterated RatingHoldLow
5/6/2020Piper SandlerBoost Price Target$8.00 ➝ $10.00Medium
5/5/2020BarclaysUpgradeEqual Weight ➝ Overweight$4.00 ➝ $7.00High
3/9/2020Needham & Company LLCReiterated RatingHoldHigh
11/15/2019Bank of AmericaUpgradeNeutral ➝ Buy$5.00 ➝ $4.00Low
11/6/2019Needham & Company LLCReiterated RatingHoldMedium
10/31/2019HC WainwrightReiterated RatingBuy$13.00High
5/24/2019Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$16.00 ➝ $4.50Low
5/23/2019JMP SecuritiesLower Price TargetOutperform$18.00 ➝ $10.00High
5/22/2019Jefferies Financial GroupLower Price TargetBuy$13.00 ➝ $8.00High
5/22/2019HC WainwrightReiterated RatingBuyMedium
4/22/2019Piper Jaffray CompaniesSet Price TargetBuy$15.00Medium
4/2/2019JMP SecuritiesBoost Price TargetMarket Outperform ➝ Market Outperform$16.00 ➝ $18.00High
4/2/2019BarclaysBoost Price TargetEqual Weight ➝ Equal Weight$6.00 ➝ $8.00High
12/4/2018Royal Bank of CanadaBoost Price TargetOutperform ➝ Positive$16.00High
11/16/2018Piper Jaffray CompaniesInitiated CoverageOverweight ➝ Overweight$15.00High
9/5/2018JMP SecuritiesBoost Price TargetOutperform$12.00 ➝ $16.00High
8/13/2018HC WainwrightReiterated RatingBuy$13.00Medium
8/9/2018Jefferies Financial GroupReiterated RatingBuy$8.50High
8/8/2018JPMorgan Chase & Co.Initiated CoverageOverweight$9.00Medium
8/7/2018Royal Bank of CanadaReiterated RatingBuy$9.00High
7/17/2018Bank of AmericaUpgradeUnderperform ➝ NeutralMedium
6/28/2018Seaport Global SecuritiesReiterated RatingNeutralLow
6/22/2018Seaport Global SecuritiesInitiated CoverageNeutralHigh
1/23/2018HC WainwrightReiterated RatingBuy$10.00Medium
1/2/2018Royal Bank of CanadaUpgradeSector Perform ➝ Outperform$6.00High
12/20/2017BarclaysInitiated CoverageEqual Weight ➝ Equal Weight$6.00Medium
11/8/2017HC WainwrightReiterated RatingBuy$10.00N/A
9/14/2017Royal Bank of CanadaInitiated CoverageSector Perform ➝ Sector Perform$6.00Low
9/6/2017HC WainwrightReiterated RatingBuy$10.00High
9/6/2017JPMorgan Chase & Co.Boost Price TargetOverweight ➝ Neutral$4.93 ➝ $9.00High
9/6/2017Jefferies Financial GroupUpgradeHold ➝ Buy$5.00 ➝ $7.00High
9/5/2017JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$6.00 ➝ $9.00High
9/5/2017Piper Jaffray CompaniesReiterated RatingOverweight$13.00 ➝ $15.00High
8/8/2017Noble FinancialReiterated RatingBuyLow
8/8/2017HC WainwrightReiterated RatingBuyLow
5/28/2017Noble FinancialReiterated RatingBuyLow
5/19/2017Needham & Company LLCReiterated RatingHoldMedium
5/6/2017Noble FinancialReiterated RatingBuyHigh
4/12/2017Needham & Company LLCReiterated RatingHoldLow
3/1/2017HC WainwrightReiterated RatingBuy$10.00N/A
2/28/2017Jefferies Financial GroupBoost Price TargetPositive$3.50 ➝ $6.00N/A
2/16/2017LADENBURG THALM/SH SHInitiated CoverageBuy$11.00N/A
2/13/2017Piper Jaffray CompaniesReiterated RatingOverweight$8.00N/A
1/23/2017(FBRC)Reiterated RatingOutperformN/A
12/16/2016JMP SecuritiesUpgradeMarket Perform ➝ Outperform$10.00N/A
11/8/2016HC WainwrightReiterated RatingBuyN/A
11/8/2016(FBRC)Reiterated RatingBuy$6.00N/A
9/8/2016(FBRC)Reiterated RatingBuyN/A
8/12/2016Piper Jaffray CompaniesUpgradeNeutral ➝ Overweight$5.00 ➝ $8.00N/A
8/5/2016HC WainwrightReiterated RatingBuyN/A
8/5/2016JPMorgan Chase & Co.Reiterated RatingHoldN/A
8/5/2016Jefferies Financial GroupBoost Price TargetHold$2.00 ➝ $3.00N/A
8/4/2016JMP SecuritiesDowngradeOutperform ➝ Market PerformN/A
(Data available from 8/2/2016 forward)
BioCryst Pharmaceuticals logo
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase I clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. BioCryst Pharmaceuticals, Inc. has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. The company was founded in 1986 and is headquartered in Durham, North Carolina.
Read More

Today's Range

Now: $16.10
Low: $16.08
High: $16.57

50 Day Range

MA: $16.20
Low: $13.28
High: $17.26

52 Week Range

Now: $16.10
Low: $3.30
High: $17.74


1,778,336 shs

Average Volume

5,041,360 shs

Market Capitalization

$2.86 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of BioCryst Pharmaceuticals?

The following Wall Street sell-side analysts have issued reports on BioCryst Pharmaceuticals in the last twelve months: Bank of America Co., Barclays PLC, Cowen Inc, Evercore ISI, HC Wainwright, JPMorgan Chase & Co., Needham & Company LLC, Piper Sandler, Royal Bank of Canada, TheStreet, and Zacks Investment Research.
View the latest analyst ratings for BCRX.

What is the current price target for BioCryst Pharmaceuticals?

8 Wall Street analysts have set twelve-month price targets for BioCryst Pharmaceuticals in the last year. Their average twelve-month price target is $16.00, suggesting a possible downside of 0.6%. Cowen Inc has the highest price target set, predicting BCRX will reach $21.00 in the next twelve months. Bank of America Co. has the lowest price target set, forecasting a price of $6.00 for BioCryst Pharmaceuticals in the next year.
View the latest price targets for BCRX.

What is the current consensus analyst rating for BioCryst Pharmaceuticals?

BioCryst Pharmaceuticals currently has 2 hold ratings and 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe BCRX will outperform the market and that investors should add to their positions of BioCryst Pharmaceuticals.
View the latest ratings for BCRX.

What other companies compete with BioCryst Pharmaceuticals?

How do I contact BioCryst Pharmaceuticals' investor relations team?

BioCryst Pharmaceuticals' physical mailing address is 4505 EMPEROR BOULEVARD SUITE 200, DURHAM NC, 27703. The biotechnology company's listed phone number is (919) 859-1302 and its investor relations email address is [email protected] The official website for BioCryst Pharmaceuticals is